Urinary CD8+HLA-DR+ T Cell Abundance Non-invasively Predicts Kidney Transplant Rejection

Emil Grothgar1,2, Nina Goerlich1,2,3, Bjoern Samans4‡, Christopher M. Skopnik1,2, Diana Metzke1,2, Jan Klocke1,2, Luka Prskalo1,2, Paul Freund1,2, Leonie Wagner1,2, Michael Duerr1, Mareen Matz3, Sven Olek4, Klemens Budde1, Alexander Paliege5 and Philipp Enghard1,2†‡

1 Department of Nephrology and Intensive Care, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2 German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany, 3 Berlin Institute of Health (BIH) at Charité–Universitätsmedizin Berlin, Berlin, Germany, 4 Ivana Türbachova Laboratory for Epigenetics, Precision for Medicine GmbH, Berlin, Germany, 5 Universitätsklinikum Carl Gustav Carus, Dresden, Germany

Early detection of kidney transplant (KT) rejection remains a challenge in patient care. Non-invasive biomarkers hold high potential to detect rejection, adjust immunosuppression, and monitor KT patients. So far, no approach has fully satisfied requirements to innovate routine monitoring of KT patients. In this two-center study we analyzed a total of 380 urine samples. T cells and tubular epithelial cells were quantified in KT patients with graft deterioration using flow cytometry. Epigenetic urine cell quantification was used to confirm flow cytometric results. Moreover, a cohort of KT patients was followed up during the first year after transplantation, tracking cell subsets over time. Abundance of urinary cell counts differed in patients with and without rejection. Most strikingly, various T cell subsets were enriched in patients with T cell-mediated rejection (TCMR) compared to patients without TCMR. Among T cell subsets, CD8+HLA-DR+ T cells were most distinctive (AUC = 0.91, Spec.: 95.9%, Sens.: 76.5%). Epigenetic analysis confirmed T cell and tubular epithelial cell quantities as determined by flow cytometry. Urinary T cell abundance in new KT patients decreased during their first year after transplantation. In conclusion urinary T cells reflect intrarenal inflammation in TCMR. T cell subsets yield high potential to monitor KT patients and detect rejection. Hereby we present a promising biomarker to non-invasively diagnose TCMR.

Keywords: transplantation, kidney, urine, T cell, biomarker, CD8+HLA-DR+, allograft acute rejection, tubular epithelial cell
INTRODUCTION

With a global prevalence of 9–15%, and rising, chronic kidney disease is a major contributor to morbidity and mortality worldwide (1, 2). Kidney transplantation is the therapy of choice in end stage kidney disease (3). However, allograft rejection (AR) leading to reduced allograft function or even graft loss remains a major challenge affecting more than 10 % of patients within the first year after transplantation (4). Established parameters like serum creatinine and proteinuria do not provide definite information about graft pathology and only increase once allograft function is already impaired (5). Transplant biopsy, the diagnostic gold standard to detect rejection, is limited by its invasive nature.

Previous studies discovered that non-invasive biomarkers hold high potential to detect rejection, adjust immunosuppression and monitor kidney transplant (KT) patients (6, 7). Various omics-based urinary biomarkers correlated with kidney inflammation and rejection (8–10). Apart from soluble factors, urine samples serve as non-invasive source for cellular components derived from the allograft. Such urinary cells hold potential as AR biomarkers since they may reflect detrimental processes in the transplant. Our group previously demonstrated that urinary cells can be used to monitor kidney damage and kidney inflammation precisely (11, 12). Other groups linked urine-derived cells to AR (13–15). More specifically, urinary HLA-DR+ cells and CD8+ T cells analyzed by flow cytometry (FC) have been suggested as promising biomarkers to detect rejection (13, 15–18). Previous trials also reported tubular epithelial cells (TEC) to represent damage in AR (19–21). Our group recently developed a biomarker combination involving urinary T cells and TEC detected by FC to identify patients with kidney transplant rejection (22).

However, many of the proposed biomarkers showed insufficient sensitivity and specificity, and were often only analyzed in small and single-centered explorative trials. Accordingly, diagnostic yield of promising biomarkers could not be proven in confirmatory trials if they had been done at all.

The current study extends previous research by (a) validating our previous findings in a multi-center setting, (b) adding an additional method (epigenetic qPCR analysis) proving the concept of urinary cells as non-invasive biomarker of rejection, (c) performing deeper phenotyping of urinary T cells and (d) describing urinary cell population trajectories during the first year after kidney transplantation to determine biomarker applicability.

### METHODS

#### Patients

380 urine samples of KT patients were analyzed in three different cohorts. Detailed patient characteristics are shown in Table 1, schematic illustration of cohorts is presented in Figure 1.

For cohort 1, we collected 90 urine samples between 2019 and 2021 for flow cytometric analysis from patients with graft deterioration and diagnostic biopsy of the Department of Nephrology, Charité University Hospital, Berlin and from Carl Gustav Carus University Hospital, Dresden, Germany.

For cohort 2, between 2010 and 2018, 218 urine samples were collected from patients at the Department of Nephrology, Charité University Hospital, Berlin and were subject to epigenetic analysis. Among these samples, 164 were collected from patients with graft deterioration and, as control group, 54 from patients with stable graft function, defined as no fluctuation of more than +/− 0.3 mg/dl creatinine compared to the prior visit. Professional diagnoses by board certified nephropathologists from renal biopsies served to uniquely group graft deterioration and patients with already commenced rejection therapy were excluded from the study.

For cohort 3, 72 samples from newly transplanted patients were collected as follow-up during the first year after transplantation. Differences in urinary cell trajectories during that period may prospectively identify patients developing rejection. Planned urine sample acquisitions at one, 3 and 12 months after transplantation were subject to variation in

### Table 1 | Patient characteristics.

| Characteristic | Cohort 1 | Cohort 2 | Cohort 3 |
|---------------|---------|---------|---------|
| Mean age in years ± SD | 55 (± 14) | 51 (± 16) | 54 (± 13) |
| Male/Female | 54/36 | 100/41 | 19/17 |
| Mean years post KT ± SD | 6 (± 7) | 5 (± 6) | First year follow-up |

Demographic details of patients included in statistical analysis. Patients who failed quality control for epigenetic analysis are not show.
FIGURE 1 | A total of three different cohorts were analyzed in this trial. Cohort 1 included 90 kidney transplant (KT) patients from two hospitals (Charité University Hospital, Berlin, Germany and Carl Gustav Carus University Hospital, Dresden, Germany) who underwent kidney biopsy due to graft deterioration. Patients were categorized by histopathological diagnosis and urine samples were analyzed by flow cytometry. In cohort 2, urine samples of 218 KT patients were subject to epigenetic qPCR analysis. 164 patients of cohort 2 underwent kidney biopsy because of graft deterioration, 54 stable KT patients served as a control group. Cohort 3 included 36 KT patients. Urine samples were analyzed on three scheduled visits by flow cytometry in a follow-up setting during the first year after transplantation.

schedule due to the COVID-19 pandemic. Sample collection was done at the Department of Nephrology, Charité University Hospital, Berlin.

Sample Preparation
For cohort 1 and 2, we collected urine samples up to 72 h prior to transplant biopsy. Samples from prospective cohort (cohort 3) were collected on scheduled follow-up visits. We used spontaneously voided urine. We developed a urine-cup-based fixation system with imidazolidinyl urea (IU, Sigma-Aldrich) and 3-(N-morpholino)propanesulfonic acid (MOPS, Carl Roth GmbH + Co. KG) to preserve urine samples. Specimen were stored at 4°C for up to 7 days, centrifuged (600 g, 6 min) and frozen in 90% fetal calf serum (FCS) and 10% dimethylsulfoxide (DMSO) (cohort 1 and 3). Preparing samples for epigenetic qPCR analysis (cohort 2), urine specimen was centrifuged immediately (1,500 g, 10 min) and frozen at −80°C. All samples were stored at −80°C for a median of 3 years.

To conduct flow cytometry analysis, we defrosted samples in phosphate-buffered saline (PBS), pH 7.2 with 0.2% bovine serum albumin (BSA) and 2 mM Ethylenediaminetetraacetic acid (EDTA) (PBE) and strained through a 30 µm cell strainer (Miltenyi Biotec). PermWash 10X Solution (BD) was used to permeabilize cells for intracellular staining of TEC. Fc receptors were blocked with FcR Blocking Reagent (human) (Miltenyi Biotec) to reduce unspecific binding and labeled for 15 min on ice with fluorochrome-conjugated monoclonal antibodies in the dark. The following antibodies were used: for T cells anti-CD3-APCeF780 (eBioscience, SK7, mo IgG1k), -CD4-PEVio770 (Miltenyi Biotec, REA623, REA) -CD8-APC (Biolegend, SK1, mo IgG1k) -CD45RO-PE (Biolegend, UCHL1, mo IgG1k2), -CD45-BUV805 (BD, 3D12, rat IgG1ak), -CCR7-BV421 (Biolegend, G043H7, mo IgG2ak), -HLA-DR-BUV395 (BD, G46-6, mo IgG2ak), -CD28-FITC (Biolegend, CD28.2, mo IgG2b) and for tubular epithelial cells anti-Cytokeratin-FITC (Miltenyi Biotec, CK3-6H5, mo IgG1k), -Vimentin-APC (Miltenyi Biotec, REA409, REA), -CD10-PEVio770 (Miltenyi Biotec, REA877, REA), -CD13-APCVio770 (Miltenyi Biotec, REA263, REA), -CD227-PE (Miltenyi Biotec, REA448, REA), -CD326-BV711 (Biolegend, 9C4, mo IgG2b). Samples were analyzed on a BD FACSymphony™ A5 Cell Analyzer. Gating strategies are depicted in Figures 2A,B. Acquired cell numbers were normalized to a volume of 100 mL urine. FC data was analyzed with FlowJo 10.7 (BD Biosciences).

For epigenetic analysis, DNA from urine was obtained, processed, and analyzed using the method published by Pradhan et al. with some modifications (24). Workflow for epigenetic analysis of urine samples is depicted in Figure 2D. In short, urine sediment (~75 µl) was lysed by adding 67 µl lysis buffer [54.25 µl ATL buffer (Qiagen), 9 µl Proteinase K (30 mg/ml, CAS 39450-01-6)], and 3.75 µl spiking plasmid essential for absolute quantification (400.000 copies/µl, Genscript) to urine sediment followed by an incubation step (56°C for 1.5 h, 900 rpm) to make genomic DNA of urinary nucleated cells accessible for bisulfite-treatment. Bisulfite-conversion was performed by adding 270
µL ammonium bisulfite [65–75% (w/w), CAS-No.: 10192-30-0] and 90 µL of tetrahydrofurfuryl alcohol (THFA, purity ≥ 98%, CAS No.: 97-99-4). After bead-based purification (Dynabeads My Silane Genomic DNA Kit, Invitrogen), a qPCR-based approach (demethyl-specific primers and probes) was used to determine CD3+ and CD3+CD8+ T cells and proximal TEC based on cell type-specific demethylated genomic regions. Cell type-specific epigenetic markers were identified by bisulfite-sequencing and cell counts were calculated according to Baron et al. (25) (Supplementary Figure 1). Oligonucleotides for bisulfite-sequencing and for demethyl-specific qPCR are listed in Supplementary Table 1.

**Results**

**Urinary T Cell Abundance Is Enriched in TCMR**

To study populations of T cells and TEC derived from urine in patients with kidney graft deterioration, we grouped participants based on the results of their KT biopsy. In cohort 1, 17 patients were diagnosed with TCMR, 24 patients with BR, 6 patients showed ABMR, 21 patients were grouped as noRX and 22 patients presented with other specific pathologies on their biopsy results. All 90 urine samples of this cohort were analyzed by FC. Patients with inconclusive biopsy results were excluded from statistical analysis. Stack plots shown in Figure 3A give an overview of cell counts per population in each group. Patients with TCMR presented with the most urinary cells in total (26,061 cells/100 ml urine on average). Together with ABMR, patients with TCMR had the highest fraction of urinary immune cells (combined CD4+ and CD8+ fraction: 40–46%, Figure 3B). In contrast, patients with BR, noRX or other graft pathologies presented predominantly with distal TEC (Fraction: 80–88%, Figure 3B). The fewest urinary cells were found in patients with noRX (2,743 cells/100 ml urine on average). Patients with TCMR presented with significantly increased urinary CD8+ T
FIGURE 3 | Absolute cell counts recorded by flow cytometry in patients undergoing renal biopsy due to graft deterioration. Patients are subdivided into five groups based on histopathological results from biopsy. (A) Stack plot for population proportions. Each stack illustrates the mean absolute cell count per population in each group. (B) Pie charts representing composition of urinary cells (selected populations) per group. (C) CD4+ and CD8+ T cell counts per 100 ml urine shown for different biopsy groups. (D) Proximal and distal TEC counts per 100 ml urine shown for different biopsy groups. Significance levels indicate comparison with TCMR; ns, no significance; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. TCMR, T cell-mediated rejection; BR, Borderline rejection; ABMR, antibody-mediated rejection; noRX, no rejection; other, other pathologies; TEC, tubular epithelial cell.

cell counts per 100 ml urine compared to patients with other biopsy results (TCMR vs. BR: p < 0.0001; TCMR vs. ABMR: p < 0.05; TCMR vs. noRX: p < 0.0001, TCMR vs. other: p < 0.01). CD4+ T cells showed a likewise tendency (TCMR vs. BR: p < 0.0001; TCMR vs. ABMR: p < 0.05; TCMR vs. noRX: p < 0.0001, TCMR vs. other: p < 0.001; Figure 3C).

In addition to T cells, we quantified subsets of urinary TEC (Figure 3D). Schematic overview of analyzed TEC populations is depicted in Figure 2C.1. Proximal TEC, defined as Cytokeratin+, CD10+ and CD13+, did not differ significantly between patient groups. In contrast, cell counts of distal TEC (Cytokeratin+, CD227+, CD326+) were higher in patients with TCMR than in patients with noRX (p < 0.05). The ratio of T cells and TEC did not improve discrimination between groups.

Epigenetic Analyses Qualitatively Confirm T Cell and TEC Quantities as Determined by Flow Cytometry

For validation purposes, we assessed urinary cells by epigenetic qPCR analysis. In 218 urine samples from kidney transplant patients, we quantified T cells and TEC. The cohort consisted of 164 KT patients with graft deterioration and suspected rejection undergoing transplant biopsy and 54 KT patients with stable kidney function without biopsy as control group. Patients undergoing biopsy were grouped based on histological results. One hundred forty-one samples passed quality control for epigenetic qPCR analysis. They were included in statistical analysis and are depicted in Figure 4. Patients with TCMR showed significantly more CD3+ T cells and CD8+ T cells than patients with noRX or than the control group. Quantity of CD3+ or CD8+ T cells did not discriminate between patients with TCMR and patients with BR or other diagnoses. Epigenetic quantification of proximal TEC showed no difference between disease groups. Therefore, epigenetic qPCR analyses confirmed FC findings showing significantly different amounts of urinary T cells in TCMR, with however imperfect delineation from other patients.

Subsets of Urinary CD8+ T Cells Enable Improved Discrimination of TCMR

Since CD8+ T cell populations derived from urine showed significant differences in patients with TCMR and patients with other causes of graft deterioration, we further investigated their subsets and activation to optimize their potential as biomarkers to detect rejection. Subsets were quantified for naïve, TEMRA effector memory and center memory T cells. Schematic overview of T cell subsets is depicted in Figure 2C.2. Moreover, HLA-DR+ and CD28+ expression as activation marker was analyzed.
Most strikingly among CD8+ T cells were CD8+HLA-DR+ and CD8+CD45RO+CCR7- (T effector memory cell, TEM) (Figure 5A, representative gating strategy including isotype controls: Figures 5D,E). Next, we assessed if our analyzed CD8+ subsets were able to distinguish patients with TCMR from all patients without TCMR and found a significant separation between these two groups (noTCMR = BR + ABMR + noRX + others; n = 73, TCMR vs. no TCMR: p < 0.0001; Figure 5B). To assess the diagnostic ability of CD8+HLA-DR+ and CD8+CD45RO+CCR7-, we calculated ROC curves (displayed in Figure 5C). The area under the curve (AUC) to diagnose TCMR using CD8+TEM cells was 0.89. CD8+HLA-DR+ T cells yielded an even better AUC value of 0.91, resulting in the most promising biomarker to distinguish patients with TCMR from all other patients. Setting a cut-off of 262.5 CD8+HLA-DR+ T cells/100 ml urine shows a sensitivity of 76.47% and a specificity of 95.89% to diagnose TCMR.

### Urinary T Cell and TEC Abundance Remain Low Over Time in the First Year After Kidney Transplantation

The first year after kidney transplantation is characterized by a particular high risk for rejection. The intrarenal reorganizing and adaptation processes in that time period after KT may however affect the applicability of biomarkers to detect rejection. In order to assess the applicability of our biomarkers in that time period, we analyzed urine samples of 36 newly transplanted patients. Our goal was to analyze three samples per patient, obtained one, 3 and 12 months after transplantation. Due to COVID19 regulations, clinic visits were canceled or changed to telemedicine visits, resulting in 9 patients each donating only one sample, while 18 other patients only provided two samples during the first year after transplantation. Nine patients fulfilled the initially planned regime of three visits including sample collections (cell trajectories for each individual patient are depicted in Supplementary Figure 3). Only two biopsy proven rejections occurred, diagnosed 3 and 4 months after the last visit and urine analysis in this trial. Therefore, no meaningful comparison of urinary cell counts and rejection was possible.

All included patients showed sufficient graft function 12 months after transplantation (creatinine mean 1.77 mg/dl, range 0.9–4.05 mg/dl). Figures 6A–D shows the trajectory of cell counts for CD4+ T cells, CD8+ T cells, proximal TEC, and distal TEC within the first year post transplantation. T cell counts in stable KT patients were low after first month post transplantation (median CD4+: 277 cells/100 ml urine; median CD8+: 506 cells/100 ml urine) and even showed a tendency to decrease over the first year after KT. The trajectories provide insights into regular development of urinary cell counts in patients without complications (defined as biopsy proven rejection, surgical complications or transplant associated hospitalization). Figure 6E shows progression of urinary CD8+ HLA-DR+ T cell populations. Applying our prior calculated cut-off for diagnosing TCMR (line), median cell counts were below cut-off level already 1 month after transplantation. These results suggest that our urine FC biomarker can feasibly be used within the first year after transplantation.

### DISCUSSION

In this first multicenter study on FC urine analysis in KT patients, we reveal CD8+HLA-DR+ T cells as a potential TCMR biomarker with high precision. Urine FC findings were validated via epigenetic analysis and longitudinal analysis of urinary cell abundance over the first year after KT suggest that the biomarker can be applied even in this early, AR-prone phase.
FIGURE 5 | CD8+ T cell subsets as biomarker for detection of KT rejection. (A) Cell counts for CD8+HLA-DR+ and CD8+TEM per biopsy group. (B) Cell counts from patients with TCMR compared to all other patients (\(=\) no TCMR). (C) ROC curves to distinguish TCMR from no TCMR. Representative FC gating for CD8+HLA-DR+ and CD8+TEM in (D) TCMR patients and (E) noRX patients. Isotype controls are displayed as blue, while full stains are represented in red. Significance levels indicate comparison with TCMR; ns, no significance; \(* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001\). TCMR, T cell-mediated rejection; BR, Borderline rejection; ABMR, antibody-mediated rejection; noRX, no rejection; other, other pathologies; no TCMR, no T cell-mediated rejection; AUC, area under the curve; TNV, naïve T cells; TEM, T effector memory cells; TCM, T central memory cells; TEMRA, T effector memory cells re-expressing CD45RA.
The Amount of Urinary T Cells Differs Significantly in Patients With and Without TCMR

Urinary T cell counts are significantly increased in TCMR. Our findings regarding CD8+ T cells distinguishing TCMR from other groups are consistent with results of other prior studies (16–18, 22). Abundance of T cells derived from urine even correlated with histopathological findings like tubulitis and interstitial inflammation. This underlines their ability to mirror graft pathology (22). In line with previous research, our findings emphasize the crucial role of CD8+ T cells in rejection. However, while the vast majority of past studies analyzed very small samples sizes, we propose our findings to be more robust due to a larger patient group with rejection and a multicenter setting.

Urinary TEC are abundant in all patient groups with graft deterioration. Contrary to our initial beliefs, we could not show differences in patients with rejection and without rejection, except for significantly more distal TEC in TCMR compared to noRX. The reason for that might be TEC reflecting unpecific kidney damage irrespective of the cause. Additionally, urinary TEC may also reflect increased turnover of the renal epithelium.

Epigenetic qPCR Analyses Qualitatively Confirmed T Cell and TEC Quantities as Determined by Flow Cytometry

As predicted and assessed by FC, we found higher T cell populations in patients with TCMR using epigenetic qPCR. These findings are in line with abundant previous research stressing T cells’ potential as diagnostic tool (13, 16, 17). Epigenetic analysis has been utilized in KT biomarker development in regard to donor-derived cell-free DNA analysis before (27). However, to our knowledge it has not been adapted to analyze urinary cell populations in AR, making this the first trial to apply epigenetic qPCR analysis of urinary cells in patients with graft deterioration. The epigenetic qPCR is an established method for quantifying immune cells in blood or tissues and was used in different studies before (28, 29). Here, this method was applied in addition to FC to validate our findings with a complementary method. Epigenetic qPCR enabled us to analyze samples frozen without any additives stabilizing the cellular integrity as a prerequisite for FC. Using epigenetic qPCR we were able to confirm significantly higher median T cell counts in the TCMR group compared to noRX or Control group in an
Subsets of Urinary CD8+ T Cells Enable Improved Discrimination of TCMR

We found activated CD8+ TEM and CD8+ HLA-DR+ T cell subsets to separate patients with TCMR best from all other examined groups. Pathophysiologically, this makes a lot of sense, since these subsets are suspected to drive tubulitis and interstitial inflammation in AR. Our findings are also in line with previous research, describing HLA-DR positive cells in urine samples with AR (13, 15, 16). With CD8+ HLA-DR+ T cell counts as TCMR biomarker, we surpassed the diagnostic ability of our previously proposed FC TCMR biomarker (22). CD8+ HLA-DR+ cells also show a better performance than transcriptomics and sophisticated urinary protein analyses (9). We think, an implementation of specific urinary cell populations, such as CD8+ HLA-DR+ T cells, to other combined biomarker types, such as Q Score/Qsant, could provide powerful precision to diagnose AR (10). However, detection of patients with ABMR via FC remains challenging.

Long-Term Follow-Up of KT Patients Shows Low Amounts of Urinary T Cells and TEC in the First Year in Patients Without Rejection

When examining trajectories of urinary cells within the first year after transplantation, we discovered, as predicted, only moderate urinary cell counts which showed a tendency to decrease over time in patients without rejection episodes. Existing trials assessing prediction of rejection episodes by urine analysis in follow-up settings focus on gross proteinuria (30, 31) or on specific immune cell associated metabolites (32, 33). Our study therefore extends previous findings, shifting its focus on cell populations and their trajectories, which have not been described in a longitudinal setting before. Plus, our results show that cut-off levels for CD8+ HLA-DR+ T cells to diagnose rejection can be applied within the first months after transplantation.

Practical Implications

Although further studies are needed to draw definitive conclusions, results of our trial present evidence that detailed phenotyping of urinary immune cells with FC provides a promising approach to monitor KT patients and detect rejection. With CD8+ HLA-DR+ T cells revealing the best performance in diagnosing TCMR and the broad availability of FC in routine laboratories, an implementation into clinical care could be realized using existing infrastructure. As suggested by 1 year-trajectories, our biomarker could also be applied within the first year after transplantation and add value in monitoring KT patients.

Limitations

First, although we conducted a multicentric approach to assess diagnostic performance of urine FC, sample sizes are still confined and rejection incidence (fortunately) is relatively low, making a final evaluation of the diagnostic quality challenging. However, we were able to include patients from two different centers and achieve promising distinction of patients with TCMR from others using FC. Future experimental studies are needed to fully uncover the diagnostic ability of T cell subsets. Second, predictive utility of our non-invasive biomarker candidates remains inconclusive due to low rejection prevalence within the first year in our cohort. Nevertheless, we were able to describe cell population trajectories and share insights into processes within the first year after transplantation. We propose a multicentric longitudinal prospective trial including KT patients to analyze urine samples by FC at regular clinic visits for a longer time span. Lastly, urine FC comes along with certain challenges, such as autofluorescence and issues in investigating rare cell subsets. Therefore, an even deeper phenotyping of immune cells with FC seems effortful. To gain deeper insights, other methods such as mass cytometry or single cell sequencing could provide a solution. More studies are needed to achieve a more fine-grained understanding of “urine prints” among KT patients with graft deterioration. These disease-specific cell patterns might mirror intrarenal pathologies and provide innovative diagnostic tools.

CONCLUSION

The current study is a unique investigation phenotyping urinary immune cells by FC as a biomarker to detect KT rejection. We extend previous research by examining urinary cell populations in a multicenter setting and by validating findings conducting epigenetic qPCR analysis. Moreover, this trial includes a longitudinal design to determine biomarker applicability during the most prone timespan for rejection—the first year after transplantation. Our data shows that urinary CD8+ HLA-DR+ T cell have the highest potential to diagnose TCMR, with a cut-off that can be implemented during the first year after transplantation. This study lays the foundation and might catalyze future research exploring urinary immune cell signatures to non-invasively diagnose rejection and monitor KT patients.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Charité EA1/284/19. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

EG and NG conducted flow cytometry experiments and created the manuscript. BS and SO established protocols for epigenetic
analysis of urinary cells. BS conducted all epigenetic analyses. CS, PE, and JK established the staining protocol and reviewed the article. DM, LW, PF, and LP provided material and expertise in method development and reviewed the manuscript. MD and KB significantly supported patient recruitment and trial management. MM collected, stored, and processed all samples for epigenetic analysis. PE and AP conceptualized and designed this trial. PE provided intellectual content of critical importance to the work described and gave final approval of the version to be published. All authors supported manuscript writing and gave final approval of the manuscript.

**FUNDING**

This work was supported by grants from the Berlin Institute of Health (BIH) and SPARK Berlin. JK was supported by a research scholarship of the Deutsche Gesellschaft für Nephrologie (DGfN). NG was participant in the BIH Charité Junior Clinician Scientist Program funded by the Charité–Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH).

**ACKNOWLEDGMENTS**

We thank the Flow Cytometry and Cell Sorting Facility and lab managers at DRFZ for technical support and helpful insights. We thank all patients for participating.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.928516/full#supplementary-material
blood samples for immunodiagnostics. *Sci Transl Med.* (2018) 10:eaan3508. doi: 10.1126/scitranslmed.aan3508

26. R Core Team. *R: The R Project for Statistical Computing.* Available online at: https://www.r-project.org/ (accessed March 9, 2022).

27. Paul RS, Almokayad I, Collins A, Raj D, Jagadesan M. Donor-derived cell-free DNA: advancing a novel assay to new heights in renal transplantation. *Transplant Direct.* (2021) 7:3–438. doi: 10.1097/TXD.0000000000001998

28. Burska AN, Thu A, Parmar R, Bizoma I, Samans B, Raschke E, et al. Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis. *Rheumatology.* (2019) 58:2015–24. doi: 10.1093/rheumatology/kez162

29. Le Cornet C, Schildknecht K, Chornet AR, Fortner RT, Maldonado SG, Katzke VA, et al. Circulating immune cell composition and cancer risk: a prospective study using epigenetic cell count measures. *Cancer Res.* (2020) 80:1885–92. doi: 10.1158/0008-5472.CAN-19-3178

30. Belmar Vega L, Rodrigo Calabia E, Gómez Román JJ, Ruiz San Millán JC, Martin Penagos L, Arias Rodríguez M. Relationship between albuminuria during the first year and antibody-mediated rejection in protocol biopsies in kidney transplant recipients. *Transplant Proc.* (2016) 48:2950–2. doi: 10.1016/j.transproceed.2016.09.012

31. Oblak M, Mlinšek G, Kojc N, Frelih M, Buturović-Ponikvar J, Arnol M. Spot urine protein excretion in the first year following kidney transplantation associates with allograft rejection phenotype at 1-year surveillance biopsies: an observational national-cohort study. *Front Med.* (2021) 8:781195. doi: 10.3389/fmed.2021.781195

32. Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. *Am J Transplant.* (2013) 13:2634. doi: 10.1111/ajt.12426

33. Hricik DE, Augustine J, Nickerson P, Formica RN, Poggio ED, Rush D, et al. Interferon gamma ELISPOT testing as a risk-stratifying biomarker for kidney transplant injury: results from the CTOT-01 multicenter study. *Am J Transplant.* (2015) 15:3166. doi: 10.1111/ajt.13401

**Conflict of Interest:** BS and SO are employed by Precision for Medicine GmbH.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Grothgar, Goerlich, Samans, Skopnik, Metzke, Klocke, Prskalo, Freund, Wagner, Duerr, Matz, Olek, Budde, Paliege and Enghard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.